Navigation Links
P&G Response to FDA Approval of Prevacid OTC(R) 24HR
Date:5/14/2009

CINCINNATI, May 14 /PRNewswire/ -- In response to the FDA's approval of Prevacid OTC(R) 24HR, The Procter & Gamble Company issued the following statement:

(Photo: http://www.newscom.com/cgi-bin/prnh//NY17325 )

"Prilosec OTC(R) is the #1 doctor and pharmacist recommended over-the-counter heartburn remedy in the U.S.," said Tim Brown - General Manager, P&G Personal Health Care North America. "Procter & Gamble built the OTC PPI market and since 2003, millions of consumers have made Prilosec OTC their frequent heartburn remedy of choice. We don't expect that to change given our strong record of providing all day and all night heartburn relief with just one pill a day."

Procter & Gamble (P&G) is a leader in gastrointestinal health and is committed to meeting the needs of its consumers with innovative digestive wellness treatments, including top-selling brands such as ALIGN(R), ASACOL(R), METAMUCIL(R), PRILOSEC OTC(R) and PEPTO-BISMOL(R).

About PRILOSEC OTC

PRILOSEC OTC is the #1 Doctor recommended acid reducer+ and Pharmacist recommended OTC Heartburn medicine++, the first of a class of OTC heartburn medicines that treats frequent heartburn with just one pill a day, unlike most over the counter heartburn medication. Prilosec OTC is the only OTC leading heartburn medicine that can work for 24 hours with one pill a day by directly shutting down many acid pumps in your stomach when used as directed for 14 days for the treating of frequent heartburn. PRILOSEC OTC is the #1 selling OTC heartburn medicine* on the market. For more information about PRILOSEC OTC, visit www.prilosecotc.com. PRILOSEC OTC is available over-the-counter through an alliance between P&G and AstraZeneca.

About Procter & Gamble (NYSE: PG)

Three billion times a day, P&G brands touch the lives of people around the world. P&G has one of the strongest portfolios of quality, leadership brands in consumer health and wellness, including Actonel(R), Align(R), Always(R), Asacol(R), Crest(R), Enablex(R), Metamucil(R), Oral-B(R), Pepto-Bismol(R), Prilosec OTC(R), Scope(R), Tampax(R), and Vicks(R), in addition to its trusted consumer brands, including Ariel(R), Braun(R), Bounty(R), Charmin(R), Dawn(R), Downy(R), Duracell(R), Folgers(R), Gillette(R), Head & Shoulders(R), Iams(R), Lenor(R), Mach3(R), Olay(R), Pantene(R), Pampers(R), Pringles(R), Tide(R), Wella(R), and Whisper(R). The P&G community consists of over 135,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

    Contact:
    P&G Health Care External Relations
    Carlos Taveras
    513-622-4645
    Taveras.cm@pg.com

    MS&L Worldwide
    Robyn Finker
    212-468-3879
    Robyn.Finker@mslworldwide.com

++ Pharmacy Times, OTC Supplement, June 2007

* Wolters Kluwer Health, Wolters Kluwer Health Physician Recommendation Audit (April 2004-June 2007, Acid Reducer Category). Data on file.


'/>"/>
SOURCE Procter & Gamble
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... ... Michael Vick announced his retirement earlier this year from the NFL after thirteen ... in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro Bowl appearances ... yards by a quarterback (6,109) and the most rushing yards by a quarterback in ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner has ... Research Award. The award honors scholars exemplary in their capacity to communicate important ... has demonstrated the capacity to deepen the public’s understanding and appreciation of the ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Sean Fay ... Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold ... any other marketer in the last 25 years. , Now, due to changes in ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... -- New research provides evidence that an old drug may provide ... released today that will be presented at the American ... Boston , April 22 to 28, 2017. ... the oral drug levodopa has long been considered the gold ... disease progresses, the effects of the medication can partially wear ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
Breaking Medicine Technology: